For sufferers with acute myeloid leukemia (AML), rapid allogeneic hematopoietic stem cell transplantation (HCT) after major induction failure (PIF) provides long-term survival profit, in line with a research revealed on-line Dec. 10 within the Blood Most cancers Journal.
Miriam Mozaffari Jovein, M.D., from the College of Freiburg in Germany, and colleagues retrospectively assessed long-term outcomes of 220 AML sufferers present process allogeneic HCT after PIF who by no means achieved remission. Medical and molecular threat components related to therapy response and prognosis had been examined.
The researchers discovered that disease-free survival after 5 and 10 years was 25.2 and 18.7 p.c, respectively, whereas general survival charges had been 29.8 and 21.6 p.c, respectively. Nonrelapse mortality was 32.5 p.c at 10 years, and illness relapse occurred inside 10 years after allogeneic HCT in 48.8 p.c of sufferers. Associations with unfavorable prognosis had been seen for opposed molecular threat components decided at preliminary analysis, poor efficiency standing on the time of allogeneic HCT, and lengthy diagnosis-to-HCT intervals.
“Fast allogeneic HCT in AML sufferers with energetic illness represents a legitimate various to intensive remission induction and gives long-term survival and treatment in a major proportion of sufferers, highlighting the significance of allogeneic HCT as the best therapy possibility on this high-risk group,” the authors write. “Our knowledge additional suggests beginning donor search at AML analysis and to instantly proceed with conditioning and allogeneic HCT in refractory sufferers at any time when a donor is on the market.”
A number of authors disclosed ties to the biopharmaceutical business.
Miriam Mozaffari Jovein et al, Lengthy-term follow-up of sufferers with acute myeloid leukemia present process allogeneic hematopoietic stem cell transplantation after major induction failure, Blood Most cancers Journal (2023). DOI: 10.1038/s41408-023-00953-0
Copyright © 2023 HealthDay. All rights reserved.
Allogeneic HCT after major induction failure useful in leukemia (2023, December 21)
retrieved 21 December 2023
This doc is topic to copyright. Other than any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.